FORT COLLINS, Colo., April 27, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating next-generation immune therapies that focus on ...
Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) — recently uplisted to the Nasdaq in lieu of earlier acquisitions involving Cleveland BioLabs and ImQuest ...
FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune ...
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. On September 1, 2021, Cytocom officially ...
FORT COLLINS, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation ...
Statera Biopharma Inc. (Nasdaq: STAB) is in danger of being delisted from the Nasdaq exchange after a sustained dip in its stock price and allegations of defaulting on a loan that led to the ...
Fort Collins business Statera Biopharma Inc. (Nasdaq: STAB) was served last month with a petition from its creditors to involuntarily force the company into Chapter 11 bankruptcy, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results